Avidity Biosciences announced the commencement of clinical trials [NCT07250737] to provide access to delpacibart zotadirsen (AOC 1044) to eligible patients diagnosed with DMD mutations amenable to exon 44 skipping under its Managed Access Program. >> Read More: Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota (Exon 44 Skipping)
Table of Contents
What is Del-Zota Exon 44 Skipping Therapy
Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene to enable dystrophin production in people living with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44).
Read More: Mutations and Deletions Amenable to Exon 44 Skipping Therapies for Duchenne Muscular Dystrophy
Del-Zota Phase 1 Participation Criteria
People must fulfill the inclusion requirements in order to be eligible. If a person has another ailment or is undergoing treatment that could prevent them from receiving exon skipping therapy, they might not be able to participate. The complete set of inclusion and exclusion criteria can be found by clicking on this study link – NCT07250737 –.
How to Participate in the Del-Zota Clinical Trial
To participate in the Del-Zota Exon 44 Skipping Clinical Trial, you can use the contact information below. Learn More: How to Participate in Clinical Trials for Duchenne (DMD)?
Name: Clinigen Customer Service
Phone Number: 1 877 768 4303
Email: [email protected]
Read More: Clinical Trials for Duchenne (List of All Researches)
